1. Metabolic Disease

Metabolic Disease

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Metabolic Disease Related Products (570):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13443
    Exendin-4 141758-74-9 98.96%
    Exendin-4, a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
  • HY-A0190
    Ceruletide 17650-98-5 99.59%
    Ceruletide (Caerulein) is a biologically active decapeptide isolated from the skin of the Australian frog Hyla caerulea. It is a potent cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts in humans and
  • HY-17386
    Rosiglitazone 122320-73-4 99.46%
    Rosiglitazone is a potent and selective activator of PPARγ, with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a Kd of appr 40 nM for PPARγ; also an modulator of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).
  • HY-50202
    Etomoxir 124083-20-1 99.40%
    Etomoxir is a potent inhibitor of carnitine palmitoyltransferase-I (CPT-1).
  • HY-16737
    Elafibranor 923978-27-2 99.31%
    Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α (PPAR-α) and peroxisome proliferator-activated receptor-δ (PPAR-δ) with EC50 values of 45 and 175 nM, respectively.
  • HY-15409
    Empagliflozin 864070-44-0 99.91%
    Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for hSGLT-2.
  • HY-50108
    GW 4064 278779-30-9 99.42%
    GW 4064 is a potent FXR agonist with EC50 of 65 nM.
    GW 4064
  • HY-B0131
    Prostaglandin E1 745-65-3 >98.0%
    Prostaglandin E1 (Alprostadil) is a prostaglandin, which is used in the treatment of erectile dysfunction and has vasodilatory properties.
    Prostaglandin E1
  • HY-13992
    AP20187 195514-80-8 99.80%
    AP20187 is a cell-permeable molecule used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.
  • HY-50202A
    (R)-(+)-Etomoxir sodium salt 828934-41-4 99.94%
    (R)-(+)-Etomoxir sodium salt is R-form of Etomoxir sodium salt. Etomoxir is a potent inhibitor of carnitine palmitoyltransferase-I (CPT-1).
    (R)-(+)-Etomoxir sodium salt
  • HY-10451
    Canagliflozin 842133-18-0 99.48%
    Canagliflozin is a selective SGLT2 inhibitor with IC50 of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
  • HY-10838
    GW 501516 317318-70-0 99.26%
    GW 501516 is a PPARδ agonist with an EC50 of 1.1 nM.
    GW 501516
  • HY-B0285A
    Amiloride hydrochloride 2016-88-8 >98.0%
    Amiloride (hydrochloride) is a relatively selective inhibitor of the epithelial sodium channel (ENaC), used in the management of hypertension and congestive heart failure.
    Amiloride hydrochloride
  • HY-14601
    Pioglitazone hydrochloride 112529-15-4 99.53%
    Pioglitazone hydrochloride is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
    Pioglitazone hydrochloride
  • HY-17389
    Genipin 6902-77-8 99.42%
    Genipin is a cell permeable inhibitor of uncoupling protein 2 (UCP2).
  • HY-10450
    Dapagliflozin 461432-26-8 99.89%
    Dapagliflozin is a new pharmacological therapy for type 2 diabetes, and inhibits sodium/glucose cotransporter 2 (SGLT2), which results in excretion of glucose into the urine.
  • HY-15145
    SRT 1720 Hydrochloride 1001645-58-4 98.79%
    SRT 1720 Hydrochloride is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities agaiinst SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
    SRT 1720 Hydrochloride
  • HY-15304
    Dynasore 304448-55-3 99.61%
    Dynasore is an inhibitor of the GTPase activity of dynamin with an IC50 of 15 μM.
  • HY-15193
    EMD638683 1181770-72-8 99.74%
    EMD638683 is a highly selective SGK1 inhibitor with IC50 of 3 μM.
  • HY-14832
    PTC124 775304-57-9 99.88%
    PTC124 targets nonsense mutations, which insert a termination codon in the middle of the CFTR gene.